We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: body, hypofractionated, radiation, SBRT, stereotactic, toxicity | Leave a comment »
In a recent commentary, we saw that the lack of a standard of care for stereotactic body radiation therapy (SBRT) dose escalation may put patients at risk when dose limits are pushed beyond what is customarily considered effective and safe. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: body, dose, escalation, outcome, radiation, SBRT, stereotactic, toxicity | Leave a comment »
Data reported at the recent Genitourinary Cancers Symposium have shown that the toxicities associated with stereotactic body radiation therapy (SBRT) are acceptable and similar whether the radiation is give as 5 or 12 doses. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hypofractionated, radiation, SBRT, stereotactic, toxicity | 2 Comments »
In an article in the October 25 issue of The ASCO Post, Dr. Jonas de Souza of the University of Chicago has introduced a new initiative to help all cancer patients and their doctors address the increasing problems associated with the costs of cancer care. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: action, cancer, care, cost, financial, research, toxicity | Leave a comment »
An interesting new paper in Cancer has offered us a sophisticated assessment of the effects of a diagnosis of and treatment for cancer on employment and income of all adults (aged 18 and older) and of adults in their prime working years (aged from 25 and 64). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, economics, employment, financial, toxicity, Treatment | 2 Comments »
There are many details of stereotactic body radiation therapy (SBRT) that may be optimized over the coming years. Among them is the optimum treatment schedule — i.e., how far apart should the treatments be spaced? … READ MORE …
Filed under: Management, Treatment | Tagged: body, radiation, SBRT, side effect, stereotactic, toxicity | Leave a comment »
A new paper, published online today in the Journal of Clinical Oncology, suggests that stereotactic body radiation therapy (SBRT, commonly delivered using the CyberKnife system) has a higher risk for genitourinary (GU) toxicity than intensity-modulated radiation therapy (IMRT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: radiation, risk, SBRT, side effect, stereotactic, toxicity | 10 Comments »
Two recent papers have reported data relevant to the application of high-dose, image-guided, intensity-modulated forms of radiation therapy (IGRT/IMRT) in the first-line treatment of men with localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: IGRT, image-guided, IMRT, intensity-modulated, radiation therapy, side effects, toxicity | 2 Comments »
Prostate cancer patients are commonly concerned about the potential risks for side effects associated with adjuvant and salvage radiation therapy after a preceding, first-line, radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: IMRT, intensity-modulated, prostate bed, radiation, side effect, toxicity, whole pelvis | 2 Comments »
For men undergoing the combination of external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT), for treatment of prostate cancer there is a significant risk for gastrointestinal (GI) toxicity over time. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation, EBRT, gastrointestinal, IMRT, toxicity | Leave a comment »
ACR 03-12 is a Phase II clinical trial designed by the American College of Radiology to test the safety and efficacy of 82 GyE (Gray equivalent) delivered using conformal proton beam radiation therapy (PBRT) for the treatment of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: high-dose, PBRT, proton beam radiation therapy, toxicity | 2 Comments »
Over the years there have been almost no publications addressing the complications of proton beam radiation therapy (PBRT) among well-defined series of prostate cancer patients. With the number of PBRT centers now growing fast, good data on the side effects of PBRT are an urgent priority. … READ MORE …
Filed under: Management, Treatment | Tagged: complications, PBRT, proton beam, toxicity | 5 Comments »
Today’s news reports cover items on:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a comment »
Today’s important news reports address:
Filed under: Drugs in development, Management, Treatment | Tagged: antiandrogen, apoptosis, approval, arteries, brachytherapy, denosumab, iodine-125, long-term, lymphocyte, radiation therapy, stiffening, survival, toremifene, toxicity | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 